Subtle onset or changes in symptoms of ATTR-CM can indicate worsening heart failure. Learn how to track symptoms and when to seek medical attention.

Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival. Long-term ATTR-CM trial data show durable benefits ...

Life expectancy for people with ATTR amyloidosis varies, generally ranging from 3 to 15 years after symptoms appear, and depends on the specific type of the condition and any other health issues a ...

Caring for someone with ATTR amyloidosis can be physically and emotionally demanding. To reduce the chances of burnout, caregivers should also prioritize their own well-being. Factors such as ...

The same abnormal proteins that can build up in your heart when you have transthyretin cardiac amyloidosis (ATTR-CM) can also leave deposits in your spine, resulting in spinal stenosis. Spinal ...

The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion market, may have just revealed the first indication of a slowdown. For the ...

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...

ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...

Heart failure can be a scary diagnosis. But what if there’s something else going on that’s even harder to spot? Meet transthyretin cardiac amyloidosis (ATTR-CM)—a serious heart condition that is ...

59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study 69% risk reduction in ACM/ first CVH ...